» Articles » PMID: 22343890

Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma

Abstract

Medulloblastoma, the most common malignant paediatric brain tumour, arises in the cerebellum and disseminates through the cerebrospinal fluid in the leptomeningeal space to coat the brain and spinal cord. Dissemination, a marker of poor prognosis, is found in up to 40% of children at diagnosis and in most children at the time of recurrence. Affected children therefore are treated with radiation to the entire developing brain and spinal cord, followed by high-dose chemotherapy, with the ensuing deleterious effects on the developing nervous system. The mechanisms of dissemination through the cerebrospinal fluid are poorly studied, and medulloblastoma metastases have been assumed to be biologically similar to the primary tumour. Here we show that in both mouse and human medulloblastoma, the metastases from an individual are extremely similar to each other but are divergent from the matched primary tumour. Clonal genetic events in the metastases can be demonstrated in a restricted subclone of the primary tumour, suggesting that only rare cells within the primary tumour have the ability to metastasize. Failure to account for the bicompartmental nature of metastatic medulloblastoma could be a major barrier to the development of effective targeted therapies.

Citing Articles

Spatio-temporal transcriptomics of chromothriptic SHH-medulloblastoma identifies multiple genetic clones that resist treatment and drive relapse.

Kats I, Simovic-Lorenz M, Schreiber H, Sant P, Mallm J, Korber V Nat Commun. 2024; 15(1):10370.

PMID: 39609432 PMC: 11604656. DOI: 10.1038/s41467-024-54709-w.


Rodent models of tumours of the central nervous system.

Brandner S Mol Oncol. 2024; 18(12):2842-2870.

PMID: 39324445 PMC: 11619804. DOI: 10.1002/1878-0261.13729.


Intracerebellar administration of the chemokine Cxcl3 reduces the volume of medulloblastoma lesions at an advanced stage by promoting the migration and differentiation of preneoplastic precursor cells.

Ceccarelli M, Rossi S, Bonaventura F, Massari R, DElia A, Soluri A Brain Pathol. 2024; 35(1):e13283.

PMID: 38946128 PMC: 11669415. DOI: 10.1111/bpa.13283.


Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models.

Rodriguez-Blanco J, Salvador A, Suter R, Swiderska-Syn M, Palomo-Caturla I, Kliebe V J Clin Invest. 2024; 134(15).

PMID: 38885332 PMC: 11290968. DOI: 10.1172/JCI171136.


Drivers Underlying Metastasis and Relapse in Medulloblastoma and Targeting Strategies.

Holmberg K, Borgenvik A, Zhao M, Giraud G, Swartling F Cancers (Basel). 2024; 16(9).

PMID: 38730706 PMC: 11083189. DOI: 10.3390/cancers16091752.


References
1.
Forbes S, Bhamra G, Bamford S, Dawson E, Kok C, Clements J . The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008; Chapter 10:Unit 10.11. PMC: 2705836. DOI: 10.1002/0471142905.hg1011s57. View

2.
Korshunov A, Benner A, Remke M, Lichter P, von Deimling A, Pfister S . Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathol. 2008; 116(4):383-90. DOI: 10.1007/s00401-008-0422-y. View

3.
Goodrich L, Milenkovic L, Higgins K, Scott M . Altered neural cell fates and medulloblastoma in mouse patched mutants. Science. 1997; 277(5329):1109-13. DOI: 10.1126/science.277.5329.1109. View

4.
Northcott P, Korshunov A, Witt H, Hielscher T, Eberhart C, Mack S . Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2010; 29(11):1408-14. PMC: 4874239. DOI: 10.1200/JCO.2009.27.4324. View

5.
Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D . Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem. 2000; 275(37):28341-4. DOI: 10.1074/jbc.C000352200. View